| Dr Margaret Victoria Ridgeway Pollard, DO | |
|
5 Richland Medical Park Dr, Columbia, SC 29203-6863 | |
| (803) 434-6151 | |
| Not Available |
| Full Name | Dr Margaret Victoria Ridgeway Pollard |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 13 Years |
| Location | 5 Richland Medical Park Dr, Columbia, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013297977 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | TL39091 (South Carolina) | Secondary |
| 207L00000X | Anesthesiology | UO2821 (Florida) | Secondary |
| 207L00000X | Anesthesiology | 39091 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Prisma Health Richland Hospital | Columbia, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Beach Anesthesia, Llc | 6103924014 | 81 |
| Prisma Health University Medical Group | 8325950983 | 2201 |
News Archive
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.
News-Medical speaks to Professor Lola Eniola-Adefeso about her research investigating how an ignored white blood cell may cause COVID-19 deaths.
Only 35% of anaesthesiologists are carrying out a simple procedure during high-risk surgery that can make a significant impact on how well patients recover from their operations, according to new research presented today at the European Anaesthesiology Congress in Amsterdam.
Allos Therapeutics, Inc. today announced the execution of a collaborative agreement with Idis, a UK-based global company, to manage the named patient program for FOLOTYN™ (pralatrexate injection) outside of the United States. The U.S. Food and Drug Administration (FDA) has granted accelerated approval for FOLOTYN for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
› Verified 8 days ago
| Entity Name | Prisma Health University Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295763217 PECOS PAC ID: 8325950983 Enrollment ID: O20031103000238 |
News Archive
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.
News-Medical speaks to Professor Lola Eniola-Adefeso about her research investigating how an ignored white blood cell may cause COVID-19 deaths.
Only 35% of anaesthesiologists are carrying out a simple procedure during high-risk surgery that can make a significant impact on how well patients recover from their operations, according to new research presented today at the European Anaesthesiology Congress in Amsterdam.
Allos Therapeutics, Inc. today announced the execution of a collaborative agreement with Idis, a UK-based global company, to manage the named patient program for FOLOTYN™ (pralatrexate injection) outside of the United States. The U.S. Food and Drug Administration (FDA) has granted accelerated approval for FOLOTYN for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
› Verified 8 days ago
| Entity Name | Carolina Anesthesiology Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851486781 PECOS PAC ID: 9739174301 Enrollment ID: O20040415000149 |
News Archive
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.
News-Medical speaks to Professor Lola Eniola-Adefeso about her research investigating how an ignored white blood cell may cause COVID-19 deaths.
Only 35% of anaesthesiologists are carrying out a simple procedure during high-risk surgery that can make a significant impact on how well patients recover from their operations, according to new research presented today at the European Anaesthesiology Congress in Amsterdam.
Allos Therapeutics, Inc. today announced the execution of a collaborative agreement with Idis, a UK-based global company, to manage the named patient program for FOLOTYN™ (pralatrexate injection) outside of the United States. The U.S. Food and Drug Administration (FDA) has granted accelerated approval for FOLOTYN for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
› Verified 8 days ago
| Entity Name | Beach Anesthesia, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215061429 PECOS PAC ID: 6103924014 Enrollment ID: O20070530000620 |
News Archive
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.
News-Medical speaks to Professor Lola Eniola-Adefeso about her research investigating how an ignored white blood cell may cause COVID-19 deaths.
Only 35% of anaesthesiologists are carrying out a simple procedure during high-risk surgery that can make a significant impact on how well patients recover from their operations, according to new research presented today at the European Anaesthesiology Congress in Amsterdam.
Allos Therapeutics, Inc. today announced the execution of a collaborative agreement with Idis, a UK-based global company, to manage the named patient program for FOLOTYN™ (pralatrexate injection) outside of the United States. The U.S. Food and Drug Administration (FDA) has granted accelerated approval for FOLOTYN for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Margaret Victoria Ridgeway Pollard, DO 300 E Mcbee Ave Fl 4, Greenville, SC 29601-2842 Ph: (864) 522-8617 | Dr Margaret Victoria Ridgeway Pollard, DO 5 Richland Medical Park Dr, Columbia, SC 29203-6863 Ph: (803) 434-6151 |
News Archive
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.
News-Medical speaks to Professor Lola Eniola-Adefeso about her research investigating how an ignored white blood cell may cause COVID-19 deaths.
Only 35% of anaesthesiologists are carrying out a simple procedure during high-risk surgery that can make a significant impact on how well patients recover from their operations, according to new research presented today at the European Anaesthesiology Congress in Amsterdam.
Allos Therapeutics, Inc. today announced the execution of a collaborative agreement with Idis, a UK-based global company, to manage the named patient program for FOLOTYN™ (pralatrexate injection) outside of the United States. The U.S. Food and Drug Administration (FDA) has granted accelerated approval for FOLOTYN for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
› Verified 8 days ago
William D. Hyman, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 5 Richland Medical Park, Columbia, SC 29203 Phone: 803-434-2797 Fax: 803-434-7038 | |
Dr. Kamran Zargham Koranloo, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1821 Clemson Rd, Columbia, SC 29229 Phone: 803-788-5916 | |
Dr. William B Parks Iii, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1330 Taylor St, Columbia, SC 29201 Phone: 803-296-5134 Fax: 803-296-5499 | |
Jerome M. Davis, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1655 Bernardin Ave, Suite 350, Columbia, SC 29204 Phone: 803-865-4780 Fax: 803-865-4932 | |
Patrick L. Laporte, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5 Richland Medical Park Dr, Columbia, SC 29203 Phone: 803-434-6151 Fax: 803-296-5137 | |
Jenna Zauk, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5 Richland Medical Park Dr, Columbia, SC 29203 Phone: 803-434-6151 Fax: 803-296-5137 |